revisiting pd-l1 as an immunotherapy biomarker across the cancer spectrum
Published 3 years ago • 475 plays • Length 1:33:59Download video MP4
Download video MP3
Similar videos
-
1:03:55
the nuances of immunotherapy biomarker testing in solid tumors
-
58:57
navigating the complexities of biomarker testing in the expanding field of precision immuno-oncology
-
0:46
immune checkpoint inhibitors: recent progress and potential biomarkers - 3iv pd-l1 overexpression
-
2:55
blueprint project update: how comparable are the results of different pd-l1 assays?
-
23:02
immunotherapy: moving beyond pd1 and pdl1 inhibitors
-
36:47
the status of pd-l1 testing and what is next? | presented by dr. ming tsao
-
2:13
the value of pd-l1 as a biomarker beyond lung cancers
-
3:50
the role of pd-l1: is it accurate enough as a biomarker for immunotherapy response?
-
4:50
nsclc: challenges with pd-l1 as biomarker
-
6:56
all you need to know about pd-l1 by immunohistochemistry
-
6:21
lung cancer video library - pdl1 as a biomarker for first line
-
1:34
evolving role of pd-l1 as a biomarker
-
1:24
dr. lilenbaum on pd-l1 as a predictive biomarker for immunotherapy in lung cancer
-
37:31
update on immuno-oncology biomarkers
-
1:39:03
everything you need to know about biomarker testing and treatment of genomically altered nsclc
-
28:45
refining the role of immune checkpoint inhibitors in endometrial cancer
-
0:36
immune checkpoint inhibitors: recent progress and potential biomarkers - 3ii pd-l1 overexpression
-
1:12
dr. sharma on pd-l1 as biomarker for immunotherapy in bladder cancer
-
3:13
pd-l1 and alternative biomarkers in head and neck cancer